Photodynamic therapy in the treatment of choroidal neovascularization complicating central serous chorioretinopathy.
We report the favorable anatomic and functional outcome of photodynamic therapy with verteporfin in a case of chronic central serous chorioretinopathy complicated with choroidal neovascularization (CNV). This 37-year-old Chinese male with bilateral chronic central serous chorioretinopathy presented with central scotoma, reduced vision and metamorphopsia in his right eye. Fluorescein angiography (FA) disclosed macular hemorrhage, exudate and subfoveal classic CNV. Photodynamic therapy (PDT) with verteporfin was applied to the CNV according to standard protocol with 2.2-mm spot size. Best-corrected visual acuity (BCVA) improved from 6/20 to 6/10 1 month after PDT. BCVA recovered to 6/7.5 without leakage on FA 3 months after PDT. Neither recurrent CNV lesion nor new hemorrhage was noted over 12 months of follow-up. Short-term results suggest that PDT with verteporfin for CNV secondary to central serous chorioretinopathy is a safe and effective treatment modality.
Yang
Chang-Sue
CS
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chen
Kuan-Chieh
KC
Lee
Shui-Mei
SM
Lee
Fenq-Lih
FL
D000328:Adult; D056833:Central Serous Chorioretinopathy / Q000150:complications*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010778:Photochemotherapy; D011166:Porphyrins / Q000627:therapeutic use*; D000077362:Verteporfin
D011166:Porphyrins; D000077362:Verteporfin